Harish Shantharam
Keine laufenden Positionen mehr
Karriereverlauf von Harish Shantharam
Ehemalige bekannte Positionen von Harish Shantharam
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CYMABAY THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 24.01.2024 | 22.03.2024 |
| Finanzdirektor/CFO | 22.05.2023 | 22.03.2024 | |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01.10.2011 | 01.05.2022 |
| AMGEN INC. | Corporate Officer/Principal | 01.01.2004 | 01.11.2011 |
Ausbildung von Harish Shantharam
| UCLA Anderson School of Management | Masters Business Admin |
| The University of Texas at Arlington | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Corporate Officer/Principal | 2 |
| Comptroller/Controller/Auditor | 1 |
| Director of Finance/CFO | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
- Börse
- Insiders
- Harish Shantharam
- Erfahrung
